Home LiteratureArticle Details
PMID: 11514491 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Interleukin 1 receptor antagonist gene polymorphism and restenosis after coronary angioplasty.

Heart (British Cardiac Society) ·Vol. 86 ·No. 3 ·2001-09-00 ·Pages 336-40

Francis SE, Camp NJ, Burton AJ, Dewberry RM, Gunn J, Stephens-Lloyd A, Cumberland DC, Gershlick A, Crossman DC

Abstract

Percutaneous transluminal coronary angioplasty (PTCA) is limited by the recurrence of luminal stenosis, which occurs in up to 50% of procedures. It has been shown that patient specific factors, perhaps genes, contribute to this process. To determine whether completion of healing after PTCA is part of an acute self limiting inflammatory process and whether polymorphism at important inflammatory gene loci might determine susceptibility to restenosis after PTCA. DNA samples were collected from 171 patients attending for elective PTCA in Sheffield (S) and Leicester (L), who were scheduled to undergo follow up angiography (at four months (L) or six months (S)) as part of other restenosis studies. At follow up angiography, the patients were separated into restenosers (> 50% luminal narrowing) and non-restenosers (< 50% luminal narrowing). Four DNA polymorphisms within interleukin 1 (IL-1) related loci (IL-1A (-889), IL-1B (-511), IL-1B (+3954), and IL-1RN intron 2 VNTR (variable number tandem repeat)) were genotyped using methods based on polymerase chain reaction. Significance was assessed by chi(2) analysis of the relevant contingency table, and the magnitude of effect was estimated by calculating odds ratios. The Mantel-Haenszel (MH) test was applied to summarise data across the two populations. Allele 2 at IL-1RN (IL-1RN*2) was significantly over represented in the non-restenoser group (L+S, 34% v 23% in restenosers). Furthermore, IL-1RN*2 homozygosity was increased in the non-restenoser population compared with the restenosers (MH test: p = 0.0196 (L+S); p = 0.031 (L+S, single vessel disease only), and the effect seemed to be restricted to the single vessel disease subpopulation. For other polymorphism within IL-1 related loci no significant associations were found with either restenosis or non-restenosis. IL-1RN*2 may be associated with protection from restenosis after PTCA for individuals with single vessel disease. As this polymorphism has functional significance, this finding suggests that alteration in an individual's inflammatory predisposition may modulate the blood vessel response to injury.

MeSH Terms
Alleles Angioplasty, Balloon, Coronary/methods Coronary Disease/genetics,therapy Homozygote Humans Interleukin 1 Receptor Antagonist Protein Middle Aged Polymorphism, Genetic/genetics Recurrence Sialoglycoproteins/genetics
Chemicals
IL1RN protein, human Interleukin 1 Receptor Antagonist Protein Sialoglycoproteins
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Francis S E
Cardiovascular Medicine Group, Division of Clinical Sciences, Clinical Sciences Centre, University of Sheffield, Northern General Hospital, Sheffield S5 7AU, UK.
Camp N J
Burton A J
Dewberry R M
Gunn J
Stephens-Lloyd A
Cumberland D C
Gershlick A
Crossman D C
References (25)
25 references, click to expand
  1. Temporal and spatial distribution of interleukin-1 beta in balloon injured porcine coronary arteries.
    Cardiovasc Res. 1999 Oct;44(1):156-65 PMID: 10615399
  2. Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1beta on tuberculosis.
    J Exp Med. 1999 Jun 21;189(12):1863-74 PMID: 10377182
  3. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis.
    Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):2394-400 PMID: 11073843
  4. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting.
    J Am Coll Cardiol. 2000 Dec;36(7):2168-73 PMID: 11127457
  5. The angiotensinogen gene 235T variant is associated with an increased risk of restenosis after percutaneous transluminal coronary angioplasty.
    Clin Sci (Lond). 2000 Jul;99(1):19-25 PMID: 10887054
  6. Interleukin-1 and interleukin-1 antagonism.
    Blood. 1991 Apr 15;77(8):1627-52 PMID: 1826616
  7. Interleukin-1 receptor antagonist.
    Adv Immunol. 1993;54:167-227 PMID: 8379462
  8. Effect of restenosis at one previously dilated coronary site on the probability of restenosis at another previously dilated coronary site.
    Am J Cardiol. 1993 Nov 15;72(15):1107-13 PMID: 8237797
  9. A potent genetic risk factor for restenosis.
    Nat Genet. 1993 Dec;5(4):324-5 PMID: 8298638
  10. Monokine antagonism is reduced in patients with IDDM.
    Diabetes. 1994 Oct;43(10):1242-7 PMID: 7926295
  11. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism.
    Clin Exp Immunol. 1995 Feb;99(2):303-10 PMID: 7851026
  12. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment.
    Circulation. 1995 Mar 1;91(5):1320-5 PMID: 7867168
  13. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist.
    Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1714-8 PMID: 7878046
  14. Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of restenosis after coronary angioplasty.
    Lancet. 1995 Apr 22;345(8956):1013-6 PMID: 7723497
  15. Angiotensin-converting enzyme insertion/deletion polymorphism and restenosis after coronary angioplasty in unstable angina pectoris.
    Am J Cardiol. 1996 Apr 15;77(10):875-7 PMID: 8623745
  16. Contributions of frequency distribution analysis to the understanding of coronary restenosis. A reappraisal of the gaussian curve.
    Circulation. 1996 Mar 15;93(6):1123-32 PMID: 8653832
  17. Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment.
    Hum Genet. 1996 Jun;97(6):723-6 PMID: 8641687
  18. Apolipoprotein E polymorphism does not predict risk of restenosis after coronary angioplasty.
    Atherosclerosis. 1996 Sep 6;125(2):209-16 PMID: 8842352
  19. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty.
    J Am Coll Cardiol. 1997 May;29(6):1276-83 PMID: 9137224
  20. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice.
    Circulation. 1998 Jan 27;97(3):242-4 PMID: 9462524
  21. An analysis of linkage disequilibrium in the interleukin-1 gene cluster, using a novel grouping method for multiallelic markers.
    Am J Hum Genet. 1998 May;62(5):1180-8 PMID: 9545388
  22. PIa1/a2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty.
    Am J Cardiol. 1998 Jul 1;82(1):13-6 PMID: 9671001
  23. Role of platelet glycoprotein PL(A1/A2) polymorphism in restenosis after percutaneous transluminal coronary angioplasty.
    Am J Cardiol. 1998 Aug 15;82(4):524-5 PMID: 9723646
  24. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease.
    Circulation. 1999 Feb 23;99(7):861-6 PMID: 10027806
  25. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene.
    J Exp Med. 2000 Jan 17;191(2):303-12 PMID: 10637274
Article Info
Journal
Heart (British Cardiac Society)
Abbr.
Heart
ISSN
1468-201X
Published
2001-09-00
Pages
336-40
Language
English
Region
England
NLM ID
9602087
PMCID
PMC1729906
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]